FREMONT, CA -- (MARKET WIRE) -- March 22, 2007 -- Cardima, Inc. (OTCBB: CRDM), a medical device company focused on the treatment of atrial fibrillation, announced today that the U.S. Food and Drug Administration (FDA) will convene a dispute resolution panel on April 19, 2007 to consider the approvability of Cardima’s pre-market approval application (PMA) for the REVELATION® Tx Microcatheter System for the treatment of symptoms associated with atrial fibrillation. The Medical Device Dispute Resolution Panel (MDDRP) will be comprised of medical experts who will advise the FDA in its evaluation of the safety and effectiveness of the REVELATION® Tx Microcatheter System.
